Filing Flows › Tandem Diabetes Care (TNDM) › Recalls, complaints & regulation
Tandem Diabetes Care (TNDM): recalls and clinical trials
Tandem Diabetes Care (TNDM) beyond its filings: 3 recalls in the last 12 months (12 in five years, 5 Class I); 1 active clinical trial.
Latest recalls
- 2026-10-07 · FDA device · Brand Name: Tandem t:slim mobile application Product Name: t:slim Mobile Application, iOS Model/Catalog Number: iOS software version 2.13 Software Version: iOS
- 2026-04-01 · FDA device · Tandem pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insu
- 2025-11-12 · FDA device · Tandem Mobi Insulin Pump: Description/Catalog: Tandem insulin pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. Th
- 2025-10-29 · FDA device · t:slim X2 insulin pump with Interoperable Technology, Control-IQ+ technology, REF: 1014070, 1014071, 1014072, 1014073, and User Guide when using Dexcom G7 senso
- 2025-10-01 · FDA device · t:slim X2 Insulin Pump with Interoperable Technology (with Tandem t:slim mobile app)
- 2025-09-03 · FDA device · Battery Operated infusion pumps. t:slim X2 G5, Replacement, Refurbished, REF: 1000911; t:slim X2 GS Classic, Replacement, Refurbished, REF: 1003808; t: slim X
- 2025-04-23 · FDA device · t:slim X2 Insulin Pump with Interoperable Technology
- 2025-04-23 · FDA device · Tandem Mobi Insulin Pump with Interoperable Technology
Tandem Diabetes Care's latest quarter
Tandem Diabetes Care, Q3 2026: revenue $284M (+14% year over year), operating margin -0.8%, net loss $7.1M, operating cash flow −$819K. The chart follows the revenue to costs, profit and cash.
Questions
Has Tandem Diabetes Care had any recalls?
12 recalls on file over five years from the FDA, CPSC and NHTSA; 3 in the last 12 months.
How many clinical trials does Tandem Diabetes Care have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.